30.57
-0.14 (-0.46%)
| Previous Close | 30.71 |
| Open | 30.99 |
| Volume | 2,499,003 |
| Avg. Volume (3M) | 2,033,185 |
| Market Cap | 4,853,276,672 |
| Price / Earnings (TTM) | 11.04 |
| Price / Earnings (Forward) | 23.98 |
| Price / Sales | 9.33 |
| Price / Book | 8.03 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | 10.13% |
| Operating Margin (TTM) | 7.13% |
| Diluted EPS (TTM) | 0.250 |
| Quarterly Revenue Growth (YOY) | 90.40% |
| Quarterly Earnings Growth (YOY) | -96.60% |
| Total Debt/Equity (MRQ) | 107.29% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -61.02 M |
| Levered Free Cash Flow (TTM) | -87.64 M |
| Return on Assets (TTM) | 7.26% |
| Return on Equity (TTM) | 19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | TG Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 1.00 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.74% |
| % Held by Institutions | 63.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Congress Asset Management Co | 31 Dec 2025 | 1,922,410 |
| Hood River Capital Management Llc | 30 Sep 2025 | 1,552,788 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 49.00 (JP Morgan, 60.29%) | Buy |
| Median | 44.00 (43.93%) | |
| Low | 39.00 (Goldman Sachs, 27.58%) | Hold |
| Average | 44.00 (43.93%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 32.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 15 Jan 2026 | 39.00 (27.58%) | Hold | 30.71 |
| JP Morgan | 03 Nov 2025 | 49.00 (60.29%) | Buy | 33.69 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| POWER SEAN A | 30.50 | - | 90,000 | 2,745,000 |
| WEISS MICHAEL S | 30.50 | - | 622,000 | 18,971,000 |
| Aggregate Net Quantity | 712,000 | |||
| Aggregate Net Value ($) | 21,716,000 | |||
| Aggregate Avg. Buy ($) | 30.50 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| POWER SEAN A | Officer | 08 Jan 2026 | Acquired (+) | 90,000 | 30.50 | 2,745,000 |
| WEISS MICHAEL S | Officer | 08 Jan 2026 | Acquired (+) | 622,000 | 30.50 | 18,971,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |